Thiazolidinedione (TZD), a PPAR-γ agonist, keeps HSCs quiescence in an in vivo model of hepatic fibrosis by controlling adipogenicity transcription factors, which also prevents HSCs from becoming activated shown by α-SMA immunostaining and producing collagen I with Sirius Red staining [96]. Here, PPARG is linked to Hepatic fibrosis.